A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge
<p>Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
International Journal of Immunotherapy and Cancer Research - Peertechz Publications,
2021-10-08.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection. </p> |
|---|---|
| DOI: | 10.17352/2455-8591.000033 |